BIIB Biogen Inc

$0.00 (0.00%)

BIIB Stock Analysis Overview

What this means: Biogen Inc (BIIB) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 77 means that our comprehensive methodology rates Biogen Inc above 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BIIB report

Biogen Inc (BIIB) Analyst Forecast

Next 12 months ➝Current Price$300.5052-week High$374.9952-week Low$215.77MEAN$325.79+8.42%HIGH$420.00+39.77%LOW$240.00-20.13%
  • Last Price$300.50
  • Previous Close$300.50
  • Change $0.00
  • Open$302.29
  • Volume1,431,000
  • Avg. Volume (100-day)1,963,488
  • Market Capitalization$49B
  • Days Range $297.86 - $304.80
  • 52-week Range $215.77 - $374.99
  • Dividend Yield
  • Ex. Dividend Date
  • P-E9.3
  • EPS32.39
  • Earnings Date07/28/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • Avg. Analyst Rec.
  • Beta0.444
  • PEG Ratio0.64
  • Volatility0.33
  • Average True Range0.05
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.